What is Aeromics?
Aeromics, Inc. operates at the intersection of advanced water physiology and neurology, focusing on the development of therapeutics that target aquaporin-4 (AQP4) channels. The company's flagship asset, AER-271, represents a novel pharmacological intervention designed to mitigate brain swelling following severe ischemic stroke. By addressing the underlying mechanisms of cerebral edema, Aeromics aims to redefine standard-of-care protocols for patients experiencing acute neurological trauma. The company is currently navigating the complex regulatory landscape of Phase 1 clinical trials, with a strategic roadmap that prioritizes safety, tolerability, and eventual Phase II efficacy validation. Their commitment to addressing unmet medical needs in stroke management positions them as a critical player in the biopharmaceutical sector, particularly as they translate complex biological insights into scalable clinical solutions.
How much funding has Aeromics raised?
Aeromics has raised a total of $13.3M across 5 funding rounds:
Grant
$2.3M
Private Equity
$1.3M
Debt
$1.9M
Debt
$1.5M
Private Equity
$6.4M
Grant (2009): $2.3M with participation from National Institutes of Health
Private Equity (2014): $1.3M, investors not publicly disclosed
Debt (2016): $1.9M, investors not publicly disclosed
Debt (2017): $1.5M, investors not publicly disclosed
Private Equity (2017): $6.4M, investors not publicly disclosed
Key Investors in Aeromics
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical non-dilutive funding for early-stage medical breakthroughs.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Aeromics?
With the recent influx of capital, Aeromics is poised to transition its lead candidate, AER-271, into more advanced clinical evaluation stages. The strategic roadmap involves scaling operational capacity to support Phase II efficacy trials, which will be instrumental in determining the therapeutic viability of AQP4 modulation in human populations. As the company continues to refine its clinical data, it will likely seek further partnerships or institutional support to navigate the high-barrier entry of the neurology market. The focus remains on achieving key regulatory milestones that validate the safety profile of their pipeline, ultimately aiming to provide a transformative treatment option for ischemic stroke patients worldwide. Future growth will be contingent upon the successful translation of preclinical efficacy into measurable clinical outcomes, ensuring that Aeromics remains at the forefront of neuro-therapeutic innovation.
See full Aeromics company page
